CA2261659C - Antiplaque oral composition - Google Patents
Antiplaque oral composition Download PDFInfo
- Publication number
- CA2261659C CA2261659C CA002261659A CA2261659A CA2261659C CA 2261659 C CA2261659 C CA 2261659C CA 002261659 A CA002261659 A CA 002261659A CA 2261659 A CA2261659 A CA 2261659A CA 2261659 C CA2261659 C CA 2261659C
- Authority
- CA
- Canada
- Prior art keywords
- silica
- xylitol
- bicarbonate
- weight
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
- A61K2800/222—Effervescent
Abstract
Disclosed is non-liquid oral dentifrice composition commonly in the form of powder or tablets which is characterized by an efficacious ratio of carbon dioxide source, xylitol, acid source and silicon dioxide.
Description
DESCRIPTION
Antiplaaue Oral Composition I. Field of the Invention The present invention relates to the field of oral health care preparations, and more specifically to improved oral health care preparations comprising anhydrous, solid, effervescent compositions.
II. Backaround of the Invention Sodium bicarbonate, baking soda, has been used for centuries as an aid to clean the human mouth and for the deodorizing and freshening the breath. In vitro scientific studies have shown that the bicarbonate ion has mild but significant antimicrobial properties against specific bacterial species, in particular anaerobic bacterial species, many of which have been shown to cause periodontal diseases (Newbrun E., et. al. J. Periodontal.
55, 11, 658-657, 1984). Compositions of baking soda and dilute hydrogen peroxide have been prescribed as a preventative and mild remedial treatment for gingivitis and periodontal diseases. (Randal, J.E., A.H. 2, 82-82, 1982, Rudy et al., U.S. Pat #4,971,?82). For example, the Keyes technique, named after Dr. Keyes from the National Institute of Health (NIH), is a common preventative and remedial treatment for mild to moderately severe cases of periodontitis. The Keyes technique can employ baking soda and dilute solutions of hydrogen peroxide. These agents are combined by simply dipping a toothbrush into a 1.5% to ~ 3% hydrogen peroxide solution followed immediately by spreading the peroxide-wetted toothbrush through a bed of baking soda and applying it to the teeth with a brushing motion. A major shortcoming of this method is the foul taste; as well as the resultant gum irritation. Another Keyes method uses a thick paste made of baking soda powder a.n combination with 1.5% to 3% hydrogen peroxide. The WO 98/03!54 PCT/LTS97/12460 paste is applied directly to the surface of the teeth and gums and maintained there for extended periods of time ion , the order of a few minutes to less than an hour).
However, laymen can have difficulty in preparing this paste and the compound gives rise to discomfort as a result of its foul taste and long residence time required to realize efficacy.
Many modern-age toothpaste compositions also use baking soda as the chief ingredient, presumably to add to the plaque reducing and breath deodorizing properties of the dentifrice. However, oral preparations containing the bicarbonate ion as the active component have heretofore not been demonstrated to have significant effectiveness, that is they have not been reported to show significant bactericidal properties in vivo.
Halitosis (oral malodor) has also been an unsolved physiological problem for centuries, and remains as such in the modern era. The chemical basis of halitosis lies in the concentration of mouth-bound volatile and odiferous compounds, primarily organic and inorganic sulfides as well as organic amines. These odiferous volatiles are biologically synthesized by particular microorganisms that reside in the oral cavity. Halitosis is primarily caused by certain anaerobic strains of bacteria (Rosemberg, M., Bad Breath: Research Perspectives, Ramot Publishing, 1995). Specifically, the proliferation in saliva of the anaerobic bacterial pathogen Fusobacterium Species, in combination with other anaerobes, have been shown as the major biological source of halitosis. Chemical mouthwash treatments have been recommended to treat halitosis, such as dilute solutions of chlorine dioxide; which presumably act as an oxidizing agent to rid of oral sulfides. A
major shortcoming of this method is the unproven long term safety of the chlorine dioxide solution (bleach) . Since a significant amount of the chlorine dioxide is absorbed through the mouth tissue and is sometimes ingested, ~i WO 98103154 PCTIUS971l2460 implementation of the mouthwash into the daily practice raises serious questions of safety.
Effervescent oral compositions have been taught in several US patents dating from about 1914 to the present.
For example, U.S. Patent No. 1,297,494 is directed to an effervescent, solid dentifrice comprising an acid salt and a bicarbonate salt which mutually react in the presence of moisture to produce COZ and an initially weak acid solution which contacts the surface of the teeth. Howell, U.S.
Patent 3,962,417, teaches an effervescent dentifrice for treatment against caries. Yeh, U.S. Patent 4,267,164 teaches an effervescent oral composition for the conveni-ent and effective delivery of fluoride ion to the oral cavity. Welsh, U.S. Patent 3,518,343 teaches an effer-vescent mouthwash tablet composition as a tablet form, where the binder is a specific combination of ingredients.
The prior art mentioned above teaches that combinations of baking soda and organic acids (typically , fruit acids) begin to immediately effervesce when placed in the oral cavity, thereby chemomechanically removing plaque and food debris during effervescence.
Although bicarbonate based mouthwashes or solid dentifrice products have been taught, none have been demonstrated as bonafide in vivo bactericidal agents:
Moreover, none have been proven to significantly effect an improvement to the health of the gingiva or for condi-tioning of the breath.
A further shortcoming of the prior art is the inherent instability of the effervescent compositions, since the self-sustaining effervescent reaction takes ~ place rapidly with water thus causing commercial embodi ments to be inherently unstable. This in turn results in .. the composition having an unacceptable shelf life unless it is prepared and securely packaged in am inert environ ment. Further, compositionally, the prior art compounds lack antimicrobial efficacy and have a poor taste, usually chalky or salty. The problems of developing a dentifrice WO 98/03!54 PCT/US97112460 which has both good taste and efficacy is crucial since frequent use of the composition is important to long term regulation of gingivitis and periodontitis. Finally, the plaque reducing properties of compositions in the prior art are minimal, since no plaque adsorption mechanism is provided.
III. Summary of the Invention The present invention solves these problems by uniquely formulating blends of bicarbonate salts with adsorbent silicone dioxide polymers; (b) teaching a novel mechanistic mode of action, plaque adsorption, underlying plaque reducing properties; (c) providing for the inherent stability of dentifrice compositions thereby improving shelf life; and, (d) substantially improving the flavor and cleansing sensation while maintaining efficacy, thereby creating a unique biologically active dentifrice which tastes good and is fun to use. Resulting widespread consumer compliance significantly decreases the amount of periodontal disease, and creates a novel treatment for halitosis that is both discrete and efficacious.
The present invention is directed towards non-aqueous oral compositions comprising a pharmaceutically acceptable form of bicarbonate salt, or carbonate salt, or combina-tions thereof; an amorphous silica; and a form of xylitol.
In addition to xylitol, other naturally occurring co-sweeteners can be employed, such as dextrose, mannitol;
sorbitol, fructose, and maltose. In addition the artifi-cial sweeteners saccharin; aspartame, neohesperidin dihydrochalcone, and others known to the art'may also be used in combination with the xylitol to enhance the ' sweetening and flavoring properties of the xylitol. Malto dextrin may also be used in the present invention to sweeten as well as enhance the flow and compression prop-erties of the various compositions of the present inven-tion, since these compositions are often powders that are ii subjected to manufacturing processes commonplace in the art of commercial and pharmaceutical mass production.
The relative amounts of xylitol; an anti-caries agent available from American Xyofin, to the bicarbonate and 5 silica is important to the improved efficacy of the present invention. First, the present invention's ability to control the growth of Streptococcus mutans is enhanced in comparison to the use of oral preparations using xylitol exclusively for caries prevention. This enhanced anti-streptococcus effect results because pH is controlled over time by a proper amount of bicarbonate-silicon dioxide complex. Second, even though xylitol alone is an effective bactericidal agent for Streptococcus mutans, its activity against the anaerobic pathogens is poor unless it is combined with a proper amount of bicarbonate ion and silicon dioxide. It is the control of the growth of these anaerobic pathogens which is important for the prevention of gingivitis, periodontitis and halitosis. Too much xylitol, alone or in combination with co-sweeteners, significantly reduces the dentifrice's activity against these anaerobic pathogens. However, it is also important to impart to the consumer the desire to use the product of the invention twice to thrice. daily in order to fully realize the bactericidal properties as well as plaque and odor reducing properties. Within these parameters (as discussed below) suitable mixtures of xylitol with other flavor agents are also within the scope of the invention.
The composition also contains a non-aqueous pharma ceutically acceptable acid source selected from the group consisting of organic acids, such as citric acid, tartaric ~ acid, fumaric acid, malic acid, and partial salts of these acids or mixtures thereof. The composition can optionally include a non-aqueous excipient, a non-aqueous pharma-ceutically acceptable anti-bacterial agent, and about 0.3 to 30 percent by weight of a pharmaceutically acceptable hydrogen peroxide source.
Antiplaaue Oral Composition I. Field of the Invention The present invention relates to the field of oral health care preparations, and more specifically to improved oral health care preparations comprising anhydrous, solid, effervescent compositions.
II. Backaround of the Invention Sodium bicarbonate, baking soda, has been used for centuries as an aid to clean the human mouth and for the deodorizing and freshening the breath. In vitro scientific studies have shown that the bicarbonate ion has mild but significant antimicrobial properties against specific bacterial species, in particular anaerobic bacterial species, many of which have been shown to cause periodontal diseases (Newbrun E., et. al. J. Periodontal.
55, 11, 658-657, 1984). Compositions of baking soda and dilute hydrogen peroxide have been prescribed as a preventative and mild remedial treatment for gingivitis and periodontal diseases. (Randal, J.E., A.H. 2, 82-82, 1982, Rudy et al., U.S. Pat #4,971,?82). For example, the Keyes technique, named after Dr. Keyes from the National Institute of Health (NIH), is a common preventative and remedial treatment for mild to moderately severe cases of periodontitis. The Keyes technique can employ baking soda and dilute solutions of hydrogen peroxide. These agents are combined by simply dipping a toothbrush into a 1.5% to ~ 3% hydrogen peroxide solution followed immediately by spreading the peroxide-wetted toothbrush through a bed of baking soda and applying it to the teeth with a brushing motion. A major shortcoming of this method is the foul taste; as well as the resultant gum irritation. Another Keyes method uses a thick paste made of baking soda powder a.n combination with 1.5% to 3% hydrogen peroxide. The WO 98/03!54 PCT/LTS97/12460 paste is applied directly to the surface of the teeth and gums and maintained there for extended periods of time ion , the order of a few minutes to less than an hour).
However, laymen can have difficulty in preparing this paste and the compound gives rise to discomfort as a result of its foul taste and long residence time required to realize efficacy.
Many modern-age toothpaste compositions also use baking soda as the chief ingredient, presumably to add to the plaque reducing and breath deodorizing properties of the dentifrice. However, oral preparations containing the bicarbonate ion as the active component have heretofore not been demonstrated to have significant effectiveness, that is they have not been reported to show significant bactericidal properties in vivo.
Halitosis (oral malodor) has also been an unsolved physiological problem for centuries, and remains as such in the modern era. The chemical basis of halitosis lies in the concentration of mouth-bound volatile and odiferous compounds, primarily organic and inorganic sulfides as well as organic amines. These odiferous volatiles are biologically synthesized by particular microorganisms that reside in the oral cavity. Halitosis is primarily caused by certain anaerobic strains of bacteria (Rosemberg, M., Bad Breath: Research Perspectives, Ramot Publishing, 1995). Specifically, the proliferation in saliva of the anaerobic bacterial pathogen Fusobacterium Species, in combination with other anaerobes, have been shown as the major biological source of halitosis. Chemical mouthwash treatments have been recommended to treat halitosis, such as dilute solutions of chlorine dioxide; which presumably act as an oxidizing agent to rid of oral sulfides. A
major shortcoming of this method is the unproven long term safety of the chlorine dioxide solution (bleach) . Since a significant amount of the chlorine dioxide is absorbed through the mouth tissue and is sometimes ingested, ~i WO 98103154 PCTIUS971l2460 implementation of the mouthwash into the daily practice raises serious questions of safety.
Effervescent oral compositions have been taught in several US patents dating from about 1914 to the present.
For example, U.S. Patent No. 1,297,494 is directed to an effervescent, solid dentifrice comprising an acid salt and a bicarbonate salt which mutually react in the presence of moisture to produce COZ and an initially weak acid solution which contacts the surface of the teeth. Howell, U.S.
Patent 3,962,417, teaches an effervescent dentifrice for treatment against caries. Yeh, U.S. Patent 4,267,164 teaches an effervescent oral composition for the conveni-ent and effective delivery of fluoride ion to the oral cavity. Welsh, U.S. Patent 3,518,343 teaches an effer-vescent mouthwash tablet composition as a tablet form, where the binder is a specific combination of ingredients.
The prior art mentioned above teaches that combinations of baking soda and organic acids (typically , fruit acids) begin to immediately effervesce when placed in the oral cavity, thereby chemomechanically removing plaque and food debris during effervescence.
Although bicarbonate based mouthwashes or solid dentifrice products have been taught, none have been demonstrated as bonafide in vivo bactericidal agents:
Moreover, none have been proven to significantly effect an improvement to the health of the gingiva or for condi-tioning of the breath.
A further shortcoming of the prior art is the inherent instability of the effervescent compositions, since the self-sustaining effervescent reaction takes ~ place rapidly with water thus causing commercial embodi ments to be inherently unstable. This in turn results in .. the composition having an unacceptable shelf life unless it is prepared and securely packaged in am inert environ ment. Further, compositionally, the prior art compounds lack antimicrobial efficacy and have a poor taste, usually chalky or salty. The problems of developing a dentifrice WO 98/03!54 PCT/US97112460 which has both good taste and efficacy is crucial since frequent use of the composition is important to long term regulation of gingivitis and periodontitis. Finally, the plaque reducing properties of compositions in the prior art are minimal, since no plaque adsorption mechanism is provided.
III. Summary of the Invention The present invention solves these problems by uniquely formulating blends of bicarbonate salts with adsorbent silicone dioxide polymers; (b) teaching a novel mechanistic mode of action, plaque adsorption, underlying plaque reducing properties; (c) providing for the inherent stability of dentifrice compositions thereby improving shelf life; and, (d) substantially improving the flavor and cleansing sensation while maintaining efficacy, thereby creating a unique biologically active dentifrice which tastes good and is fun to use. Resulting widespread consumer compliance significantly decreases the amount of periodontal disease, and creates a novel treatment for halitosis that is both discrete and efficacious.
The present invention is directed towards non-aqueous oral compositions comprising a pharmaceutically acceptable form of bicarbonate salt, or carbonate salt, or combina-tions thereof; an amorphous silica; and a form of xylitol.
In addition to xylitol, other naturally occurring co-sweeteners can be employed, such as dextrose, mannitol;
sorbitol, fructose, and maltose. In addition the artifi-cial sweeteners saccharin; aspartame, neohesperidin dihydrochalcone, and others known to the art'may also be used in combination with the xylitol to enhance the ' sweetening and flavoring properties of the xylitol. Malto dextrin may also be used in the present invention to sweeten as well as enhance the flow and compression prop-erties of the various compositions of the present inven-tion, since these compositions are often powders that are ii subjected to manufacturing processes commonplace in the art of commercial and pharmaceutical mass production.
The relative amounts of xylitol; an anti-caries agent available from American Xyofin, to the bicarbonate and 5 silica is important to the improved efficacy of the present invention. First, the present invention's ability to control the growth of Streptococcus mutans is enhanced in comparison to the use of oral preparations using xylitol exclusively for caries prevention. This enhanced anti-streptococcus effect results because pH is controlled over time by a proper amount of bicarbonate-silicon dioxide complex. Second, even though xylitol alone is an effective bactericidal agent for Streptococcus mutans, its activity against the anaerobic pathogens is poor unless it is combined with a proper amount of bicarbonate ion and silicon dioxide. It is the control of the growth of these anaerobic pathogens which is important for the prevention of gingivitis, periodontitis and halitosis. Too much xylitol, alone or in combination with co-sweeteners, significantly reduces the dentifrice's activity against these anaerobic pathogens. However, it is also important to impart to the consumer the desire to use the product of the invention twice to thrice. daily in order to fully realize the bactericidal properties as well as plaque and odor reducing properties. Within these parameters (as discussed below) suitable mixtures of xylitol with other flavor agents are also within the scope of the invention.
The composition also contains a non-aqueous pharma ceutically acceptable acid source selected from the group consisting of organic acids, such as citric acid, tartaric ~ acid, fumaric acid, malic acid, and partial salts of these acids or mixtures thereof. The composition can optionally include a non-aqueous excipient, a non-aqueous pharma-ceutically acceptable anti-bacterial agent, and about 0.3 to 30 percent by weight of a pharmaceutically acceptable hydrogen peroxide source.
Sufficient bicarbonate or carbonate salt is employed in the composition so that in an aqueous pH test mixture , of the composition; the acid or the acid salt is com-pletely neutralized by the bicarbonate or carbonate salt, , and that an excess of the bicarbonate or carbonate salt is employed such that a basic pH of the aqueous solution (>7), is maintained from minimum of 1 minute to about 1 hour; or greater, depending on the patient and specific composition of the present invention that is employed.
The composition can be administered as a tablet, as a powder, and as a capsule which is dispersible in human saliva. The inventors method for preparation of bicarbonate-silicon dioxide compositions incorporates a method of pharmaceutical processing named granulation.
Polyvinylpyrrolinone can be used in the present invention as the preferred granulating agent because it aids in binding the silicon dioxide polymer to the bicarbonate salt.
The plaque removal and anti-plaque properties of the composition are not fully understood. It is believed that when the composition is placed in the oral cavity, the saliva wets the composition dissolving the bicarbonate or carbonate salt and the solubilized bicarbonate or carbon-ate ion and the acid components in the resulting saliva mixture undergo a rapid acid-base reaction generating car-bon dioxide gas (effervescence). The resulting salivary solution is swept through the oral cavity; between the teeth, into crevices and cavities in between the teeth and into the juncture of the gums and teeth. It is believed that the bicarbonate or carbonate ion, the acid, acid salt components, and the acid-bicarbonate and carbonate salt components chemically loosen the plaque and other organic debris from the surface of the teeth, possibly via a s debriding type of action. The effervescent action of the saliva sweeps a portion of the loosened plaque and organic and inorganic debris from the surfaces of the teeth and gums. After the effervescence has stopped, the resulting W0 98/03154 PCTlE7S97112460 saliva mixture can be swished through the mouth to cleanse the surfaces of the teeth and gums (especially the surfaces between adjoining teeth) and to sweep out loose organic and inorganic debris. After expulsion or swallowing, it is believed that an appreciable amount of the solid bicarbonate-silica material adheres to the proteinaceous debris and mucosa which naturally resides on the surfaces of the teeth and gums. Consequently, the bicarbonate-silica complexes of the present invention are sustained in the oral cavity from minutes to hours. As a direct result of this sustansivity, plaque is adsorbed over time by the silica particles (adsorbents).
Furthermore, sodium bicarbonate (or other bicarbonate salt) is released to the saliva over time. Accordingly, the present invention causes an enhanced bacteriocidal action arising from the sustained release of the bicarbon-ate ion. A speculated mechanism for this action is as follows: Residual solid bicarbonate salt starts to dissolve immediately after swallowing, or expulsion of, the original salivary mixture. Over time (seconds to many minutes), bicarbonate salt desorbs from the sustained plaque-bound silica-bicarbonate material. This latent solubilization of the bicarbonate salt results in a sub-stantial amount of bicarbonate ion present in the salivary mixture. Of significance, studies have shown (see, e.g., Newbrun, E.; Bactericidal Action of Bicarbonate on Selected Periodontal Pathogenic Microorganisms, J.
Periodontal, 55, 11, 653, 1984), that if left in the oral cavity for over 15 minutes, concentrated solutions of bicarbonate ion have appreciable bacteriocidal action against bacteria that cause periodontal disease. Since the bicarbonate ion is sustained in the oral cavity the salivary solutions generated are mildly bacteriocidal and, hence, provide the user with a novel, effective and chemically active therapeutic treatment for preventing and treating gingivitis, periodontal diseases and halitosis.
The composition can be administered as a tablet, as a powder, and as a capsule which is dispersible in human saliva. The inventors method for preparation of bicarbonate-silicon dioxide compositions incorporates a method of pharmaceutical processing named granulation.
Polyvinylpyrrolinone can be used in the present invention as the preferred granulating agent because it aids in binding the silicon dioxide polymer to the bicarbonate salt.
The plaque removal and anti-plaque properties of the composition are not fully understood. It is believed that when the composition is placed in the oral cavity, the saliva wets the composition dissolving the bicarbonate or carbonate salt and the solubilized bicarbonate or carbon-ate ion and the acid components in the resulting saliva mixture undergo a rapid acid-base reaction generating car-bon dioxide gas (effervescence). The resulting salivary solution is swept through the oral cavity; between the teeth, into crevices and cavities in between the teeth and into the juncture of the gums and teeth. It is believed that the bicarbonate or carbonate ion, the acid, acid salt components, and the acid-bicarbonate and carbonate salt components chemically loosen the plaque and other organic debris from the surface of the teeth, possibly via a s debriding type of action. The effervescent action of the saliva sweeps a portion of the loosened plaque and organic and inorganic debris from the surfaces of the teeth and gums. After the effervescence has stopped, the resulting W0 98/03154 PCTlE7S97112460 saliva mixture can be swished through the mouth to cleanse the surfaces of the teeth and gums (especially the surfaces between adjoining teeth) and to sweep out loose organic and inorganic debris. After expulsion or swallowing, it is believed that an appreciable amount of the solid bicarbonate-silica material adheres to the proteinaceous debris and mucosa which naturally resides on the surfaces of the teeth and gums. Consequently, the bicarbonate-silica complexes of the present invention are sustained in the oral cavity from minutes to hours. As a direct result of this sustansivity, plaque is adsorbed over time by the silica particles (adsorbents).
Furthermore, sodium bicarbonate (or other bicarbonate salt) is released to the saliva over time. Accordingly, the present invention causes an enhanced bacteriocidal action arising from the sustained release of the bicarbon-ate ion. A speculated mechanism for this action is as follows: Residual solid bicarbonate salt starts to dissolve immediately after swallowing, or expulsion of, the original salivary mixture. Over time (seconds to many minutes), bicarbonate salt desorbs from the sustained plaque-bound silica-bicarbonate material. This latent solubilization of the bicarbonate salt results in a sub-stantial amount of bicarbonate ion present in the salivary mixture. Of significance, studies have shown (see, e.g., Newbrun, E.; Bactericidal Action of Bicarbonate on Selected Periodontal Pathogenic Microorganisms, J.
Periodontal, 55, 11, 653, 1984), that if left in the oral cavity for over 15 minutes, concentrated solutions of bicarbonate ion have appreciable bacteriocidal action against bacteria that cause periodontal disease. Since the bicarbonate ion is sustained in the oral cavity the salivary solutions generated are mildly bacteriocidal and, hence, provide the user with a novel, effective and chemically active therapeutic treatment for preventing and treating gingivitis, periodontal diseases and halitosis.
It is an aim of the present invention to provide a dry oral wash composition that can be inserted into the oral cavity following a meal, snack, coffee or the smoking of a cigarette in order to rinse the mouth free of organic debris and inhibit the formation of plaque.
Another aim of the present invention is to provide an anti-plaque composition that will inhibit the build-up of plaque on the teeth and inhibit the population growth of plaque bacteria in the oral cavity.
It is a further aim of the present invention to provide a good tasting efficacious oral composition that is safe for human consumption and that will be used regularly by individuals in preventing gingivitis and periodontal disease.
It is a further aim of the present invention to provide effervescent oral compositions that are capable of, adsorbing plaque biomass.
It is a further aim of the present invention to provide effervescent oral compositions that are effective in limiting the growth of odor causing bacteria.
It is a further aim of the present invention to provide oral compositions which neutralize the acids in the oral cavity and to effect a sustained neutral pH of the saliva (above pH of 7 for minutes after swallowing or expulsion).
The invention provides an effervescent tablet or capsule of effervescent powder for oral use comprising, a) a non-aqueous, water soluble pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof;
b) silica; and c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
The invention further provides a method for cleaning an oral cavity comprising the steps of: (a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1; (b) solubilizing said tablet or capsule powder; (c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
The invention further provides use of an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about .5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1, in cleaning the oral cavity of an animal.
Detailed Description of the Invention Bicarbonate ion is combined with certain silicon dioxide polymers in the present invention, at specific rations.
In the present invention, a range of 1 to 10 parts bicarbonate ion to 1 part silicone dioxide is preferred, a range of 1 to 5 parts bicarbonate ion to 1 part silica is more preferred, and a 9a range of 2 to 4 parts bicarbonate ion to 1 part silica is most preferred. The form of silicone dioxide suitable for use in the present invention is amorphous silica, while precipitated amorphous silica is preferred, and precipitated amorphous silica having a low amount of aluminium (between 0.1% and 2%) is most preferred. The most preferred silica is named ZEO-49*
and is commercially available from J.M. Huber. The same ratios hold true if a carbonate is used instead of bicarbonate.
The bicarbonate-silicone dioxide preparations of the present invention may be free flowing blends, or most preferably, as granulated mixtures milled to a size that will pass through a sieve #20 to a sieve #80. The preferred granulating agent is polyvinyl pyrrolinone (PVP) (Kollidone 30 [BASF]). The preferred solvent of granulation is water, although other solvents and granulating agents known to the art of pharmaceutical manufacturing can be employed for the preparation of the bicarbonate-silicon dioxide preparation in the present invention. The amount of granulating agent is important, since an excess will inhibit the clinical efficacy of the present invention by inactivating the plaque adsorption and sustainment properties of the xylitol-bicarbonate-silicone dioxide oral preparation. The range of granulating agent is about 1-30 parts PVP to 100 parts bicarbonate-silicone dioxide preparation, and preferably from about 3 to 15 parts PVP to 100 parts bicarbonate-silicon dioxide preparation and most preferably from about 3 to 7 parts PVP to 100 parts bicarbonate-silicon dioxide preparation.
As explained earlier, the relative amounts of xylitol to the bicarbonate ion-silicon dioxide preparation is important. A ratio of xylitol to bicarbonate-silicon dioxide of about 0.5 parts to 7 parts xylitol to 3 parts bicarbonate-silicon dioxide preparation is preferred, and a ratio of about 1.0 to 5 parts xylitol to 3 parts bicarbonate-silicon dioxide 9b preparation is more preferred, and the ratio of about 2 to 4 parts xylitol to 3 parts bicarbonate-silicon dioxide preparation is the most preferred.
Fructorse, dextrose, sorbitol, mannitol, and others referred to here as natural co-sweeteners, are not critical, but may also be used to enhance the sweetening characteristics of the present invention. The amounts of these natural co-sweeteners to the amount of xylitol are from about 1 to 60 parts co-sweetener to 30 parts xylitol;
5 and from about 1.5 parts to 40 parts co-sweetener to 30 parts xylitol, and most preferably from about 2 to 10 parts co-sweetener to 30 parts xylitol.
Sweetening agents, both artificial and natural, having a sweetness much greater than sucrose, may also be l0 employed as co-sweeteners to enhance the flavoring characteristics of the present invention. The most preferred artificial sweeteners are aspartame, saccharin, or neohesperidin dihydrochalcone, although others known to the art may also be employed. The preferred ranges for these sweetening agents is from l part sweetener to about .1 part to 50 parts xylitol, and from about 1 part sweetener to about .5 part to 25 parts xylitol, and most preferably from about 1 part to about 5 parts sweetener to about 10 parts to about 15 parts xylitol.
The fruit acids such as citric acid, tartaric acid, fumaric acid, and malic acid may also be employed in the present invention. Citric acid is preferred. The amount of fruit acid is 1 part fruit acid to about 1 to about 20 parts bicarbonate ion, and preferably about 1 part :fruit acid-to about 1.5 to l0 parts-bicarbonate ion and most preferably from about l.part fruit acid to about l.5 part to 5 parts bicarbonate ion. If a carbonate source is used in place of bicarbonate, the amount of fruit acid should be adjusted accordingly to maintain pH of neutral or greater in test solution. For example, the amount of fruit acid is 1 part fruit acid to about l to 20 parts bicarbonate ion, and preferably about 1 part fruit acid to about 1.5 to 10 parts bicarbonate ion and most preferably from about 1 part fruit acid to about 1.5 part to 5 parts bicarbonate ion.
Examples The following examples are intended to illustrate, but not to limit the present invention.
Example l:
Ingredient mass (Kg) xylitol (American Xyofin*) 1401 mannitol 250 aspartame (Nutrasweet*) 135 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49* [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
*Trade-mark lla Example 2 This example describes Applicant's preferred embodiment.
Ingredient mass (Kg) xylitol (American Xyofin) 1401 mannitol 250 aspartame (Nutrasweet) 135 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC#1) 1250 silica (ZEO-49 [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 polyvinyl pyrrolinone (PVP K-30* [FMC]) 89 magnesium stearate 20 stearic acid 65 *Trade-mark WO 98!03154 PCTIL1S97112460 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of polyvinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed. This cake was spread evenly onto trays and dried in an oven at less than 225°C until-completely dry (<1~
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about 1 to 2 hours in a tumble blender (or other blender of low shear} to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets:
Example 3: , This example describes a biologically active composi-tion with a peroxide source, which is incorporated to enhance the biological activity as we ll as cosmetic tooth whitening.
Incrredient mass (Kcr) xylitol (American Xyofin) 1560 mannitol 280 aspartame (Nutrasweet) 145 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 31 mint flavoring ~ 3.8 sodium bicarbonate (FMC #1) 1276 urea hydrogen peroxide (Robeko, N.Y.) 305 silica (ZEO-49 P.M. Huber Co.]) 418 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone (PVP K-30 [FMC]} 89 magnesium stearate 20 stearic acid 85 The sodium bicarbonate, silicon dioxide, PVP,~sodium lauryl sulfate are prepared in a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce a powder that can be tableted using a Stokes table press.
Example 4:
This example describes a biologically active composi-tion with a chlorine dioxide source, which is incorporated to enhance the biological activity, and for the treatment of halitosis.
Inaredient mass (Ka) xylitol (American Xyofin) 1560 mannitol 180 sorbitol 126 aspartame (Nutrasweet) 125 sodium lauryl sulfate (Witco) 20 chlorine dioxide source 2.5~
I - menthol crystals 35 mint flavoring 4.1 sodium bicarbonate (FMC #1) 1276 silica (ZEO-49 [J.M. Huber Co.]) 418 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone (PVP K-30 [FMC]) 89 magnesium stearate 20 stearic acid 85 The sodium bicarbonate, silicon dioxide, PVP, sodium lauryl sulfate are prepared in a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditi ons of low shear, to produce a powder that can be tableted using a Stokes table press.
Exampla 5:
This example describes a biologically active composition :with a Iodine source, which is incorporated to enhance the biological activity. , Ingredient mass (K
xylitol (American Xyofin) 1560 mannitol 280 aspartame (Nutrasweet) 145 sodium lauryl sulfate (Witco) ~ 20 1 - menthol crystals 31 mint flavoring 3.8 Povidone Iodine 33~
sodium bicarbonate (FMC #1) 1276 urea hydrogen peroxide (Robeko, N.Y.) 305 silica (ZEO-49 [J.M. Huber Co.]) 418 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone (PVP K-30 [FMC]) 89 magnesium stearate 20 stearic, acid 85 The sodium bicarbonate, silicon dioxide, PVP, sodium lauryl sulfate are prepared in a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditi ons of low shear, to produce a powder that can be tableted using a Stokes table press.
Example 6:
This example describes a highly biologically active composition with a chlorhexidine source, which is incorporated to enhance the biological activity.
Inaredient mass (Kcr) xylitol (American Xyofin) 1560 mannitol 280 aspartame (Nutrasweet) 145 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 31 mint flavoring 3.8 sodium bicarbonate {FMC #1) 1276 chlorhexidine gluconate 14.5 silica {ZEO-49 [J:M. Huber Co.]) 418 5 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone {PVP K-30 [FMC]) 89 Neohesperidin dihydrochalcone (Exime) 6 magnesium stearate 20 stearic acid 85 10 The sodium bicarbonate, silicon dioxide, PVP, sodium lauryl sulfate are prepared yin a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to 15 produce a powder that can be tableted using a Stokes table press.
Example 7 This example describes a new example.
Incrredient mass (KQ) xylitol (American Xyofin) 1401 sorbitol 125 dextrose 145 aspartame (Nutrasweet) 128 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 21 mint flavoring 3.6 sodium bicarbonate (FMC#1) 1225 silica (ZEO-49[J.M. Huber Co.]) 401 citric Acid (anhydrous crystals) 238 polyvinyl pyrrolinone (PVP
K-30 [FMC] ) 82 ~ magnesium stearate 15 stearic acid 71 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of polyvinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed. This cake was spread evenly onto trays and dried in an oven at less than 225°C until-completely dry (<1~
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about l to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend: The powder is immediately pressed into tablets.
Example 8 Ingredient mass (Kg) xylitol (American Xyofin) 140 mannitol 1800 dextrose 700 aspartame (Nutrasweet) 135 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49 [J.M. Huber Co.J) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 9 This example describes a new example. ' Ingredient mass (Ka) xylitol (American Xyofin) 950 fructose 600 mannitol 307 aspartame (Nutrasweet) 100 ~ sodium lauryl sulfate (Witco) 20 1 - menthol crystals 27 . mint flavoring 2.9 sodium bicarbonate (FMC#1) 125 0 silica (ZEO-49[J.M. Huber Co:]) 310 silica (DeGusa) 52 citric Acid (anhydrous crystals) 205 tartaric acid 53 polyvinyl pyrrolinone (PVP
K-90 [FMC] ) 61 magnesium stearate 20 stearic acid 80 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of poly-vinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed.
This cake was spread evenly onto trays and dried in an oven at less than 225C until completely dry (<1%
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve., The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets.
Example 10:
Ingredient mass (Kct) xylitol (American Xyofin) 1250 mannitol 250 fructose 280 sorbitol 292 neohesperidin dihydrochalcone (NDHC Exquinne* [Spain]) 2 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49 [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 11 Ingredient mass (Kg) xylitol (American Xyofin) 250 maltodextrin 493 avisil pH 102 (FMC) 628 aspartame (Nutrasweet) 118 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #5) 1250 silica (ZEO-49 [J.M. Huber Co.]) 410 malic acid (anhydrous crystals) 243 polyvinyl pyrrolinone (PVP K-30 [FMC]) 89 magnesium stearate 20 stearic acid 65 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of polyvinyl pyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed. This cake was spread *Trade-mark 18a evenly onto trays and dried in an oven at less than 225°C until completely dry (<lo moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in . portions over about 1 to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets.
Example 12:
Inaredient mass (Kg?
xylitol (American Xyofin) 1401 mannitol 250 natural honey powder 790 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 potassium bicarbonate 290 sodium bicarbonate (FMC #1) 1320 Silica (ZEO-49 [J.M. Huber Co.]) 496 Citric Acid (anhydrous crystals) 243 tartaric acid 72 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 13 This example describes Applicant's preferred embodiment for a mint candy composition.
Ingredient mass tKct~
xylitol (American Xyofin) 1401 mannitol 250 sorbitol 375 ~ aspartame (Nutrasweet) 108 1 - menthol crystals 25 peppermint oil 2.3 sodium lauryl sulfate (Witco) 15 sodium bicarbonate (FMC#1) 1250 silica (ZEO-49[J.M. Huber Co.]) 420 citric Acid (anhydrous crystals) 243 polyvinyl alcohol (PVA) ' 103 glycerin 196 5 polyethylenglycol (PEG-60) 22 To a steam heated stainless steel kettle charged with 196 kg of anhydrous glycerin and 103 kg of PVA the mixture is stirred until an internal temperature of 80oC is maintained. To this is added in portions, with gentle l0 stirring, a blend of xylitol, mannitol and sorbitol and sodium lauryl sulfate. The resulting viscous slurry is stirred at between 75oC - 90oC until a homogenous mixture is obtained: The slurry is allowed to cool while stirring to an internal temperature of 500-600. A blend of NaHc03, 15 SiOz, is then added followed by the citric acid. The mixture is then cooled to form a cake. This cake is cut and/or pulverized to meet packaging requirements.
Exam~,ale 14:
Ingredient mass (Ka) 20 xylitol (American Xyofin) 1401 mannitol 250 aspartame (Nutrasweet) 135 1 - menthol crystals 25 mint flavoring 3.6 sodium lauryl sulfate (Witco) 20 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49 [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 15 This example describes appetite suppressive breath mint.
Incrredient mass (KQ) xylitol (American Xyofin) 1401 mannitol 250 ~ aspartame (Nutrasweet) 135 1 - menthol crystals 25 mint flavoring 3.6 sodium lauryl sulfate (Witco) 20 sodium bicarbonate (FMC#1) 1250 silica (ZEO-49[J.M. Huber Co.]) 410 citric Acid (anhydrous crystals) 243 polyvinyl pyrrolinone (PVP
K-30 [FMC]) 89 garcinio powder 28 magnesium stearate 24 1.5 stearic acid 65 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of poly-vinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed.
This cake was spread evenly onto trays and dried in an oven at less than 225°C until completely dry (<1~
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about 1 to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets.
' It will be understood that the embodiments described herein are merely exemplary and that a person skilled in the art may make many variations and modifications without departing from the spirit and scope of the invention. All such modifications and variations are intended to be WO 98103154 PCTlUS97/12460 included within the scope of the invention as defined in the appended claims.
Another aim of the present invention is to provide an anti-plaque composition that will inhibit the build-up of plaque on the teeth and inhibit the population growth of plaque bacteria in the oral cavity.
It is a further aim of the present invention to provide a good tasting efficacious oral composition that is safe for human consumption and that will be used regularly by individuals in preventing gingivitis and periodontal disease.
It is a further aim of the present invention to provide effervescent oral compositions that are capable of, adsorbing plaque biomass.
It is a further aim of the present invention to provide effervescent oral compositions that are effective in limiting the growth of odor causing bacteria.
It is a further aim of the present invention to provide oral compositions which neutralize the acids in the oral cavity and to effect a sustained neutral pH of the saliva (above pH of 7 for minutes after swallowing or expulsion).
The invention provides an effervescent tablet or capsule of effervescent powder for oral use comprising, a) a non-aqueous, water soluble pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof;
b) silica; and c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
The invention further provides a method for cleaning an oral cavity comprising the steps of: (a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1; (b) solubilizing said tablet or capsule powder; (c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
The invention further provides use of an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about .5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1, in cleaning the oral cavity of an animal.
Detailed Description of the Invention Bicarbonate ion is combined with certain silicon dioxide polymers in the present invention, at specific rations.
In the present invention, a range of 1 to 10 parts bicarbonate ion to 1 part silicone dioxide is preferred, a range of 1 to 5 parts bicarbonate ion to 1 part silica is more preferred, and a 9a range of 2 to 4 parts bicarbonate ion to 1 part silica is most preferred. The form of silicone dioxide suitable for use in the present invention is amorphous silica, while precipitated amorphous silica is preferred, and precipitated amorphous silica having a low amount of aluminium (between 0.1% and 2%) is most preferred. The most preferred silica is named ZEO-49*
and is commercially available from J.M. Huber. The same ratios hold true if a carbonate is used instead of bicarbonate.
The bicarbonate-silicone dioxide preparations of the present invention may be free flowing blends, or most preferably, as granulated mixtures milled to a size that will pass through a sieve #20 to a sieve #80. The preferred granulating agent is polyvinyl pyrrolinone (PVP) (Kollidone 30 [BASF]). The preferred solvent of granulation is water, although other solvents and granulating agents known to the art of pharmaceutical manufacturing can be employed for the preparation of the bicarbonate-silicon dioxide preparation in the present invention. The amount of granulating agent is important, since an excess will inhibit the clinical efficacy of the present invention by inactivating the plaque adsorption and sustainment properties of the xylitol-bicarbonate-silicone dioxide oral preparation. The range of granulating agent is about 1-30 parts PVP to 100 parts bicarbonate-silicone dioxide preparation, and preferably from about 3 to 15 parts PVP to 100 parts bicarbonate-silicon dioxide preparation and most preferably from about 3 to 7 parts PVP to 100 parts bicarbonate-silicon dioxide preparation.
As explained earlier, the relative amounts of xylitol to the bicarbonate ion-silicon dioxide preparation is important. A ratio of xylitol to bicarbonate-silicon dioxide of about 0.5 parts to 7 parts xylitol to 3 parts bicarbonate-silicon dioxide preparation is preferred, and a ratio of about 1.0 to 5 parts xylitol to 3 parts bicarbonate-silicon dioxide 9b preparation is more preferred, and the ratio of about 2 to 4 parts xylitol to 3 parts bicarbonate-silicon dioxide preparation is the most preferred.
Fructorse, dextrose, sorbitol, mannitol, and others referred to here as natural co-sweeteners, are not critical, but may also be used to enhance the sweetening characteristics of the present invention. The amounts of these natural co-sweeteners to the amount of xylitol are from about 1 to 60 parts co-sweetener to 30 parts xylitol;
5 and from about 1.5 parts to 40 parts co-sweetener to 30 parts xylitol, and most preferably from about 2 to 10 parts co-sweetener to 30 parts xylitol.
Sweetening agents, both artificial and natural, having a sweetness much greater than sucrose, may also be l0 employed as co-sweeteners to enhance the flavoring characteristics of the present invention. The most preferred artificial sweeteners are aspartame, saccharin, or neohesperidin dihydrochalcone, although others known to the art may also be employed. The preferred ranges for these sweetening agents is from l part sweetener to about .1 part to 50 parts xylitol, and from about 1 part sweetener to about .5 part to 25 parts xylitol, and most preferably from about 1 part to about 5 parts sweetener to about 10 parts to about 15 parts xylitol.
The fruit acids such as citric acid, tartaric acid, fumaric acid, and malic acid may also be employed in the present invention. Citric acid is preferred. The amount of fruit acid is 1 part fruit acid to about 1 to about 20 parts bicarbonate ion, and preferably about 1 part :fruit acid-to about 1.5 to l0 parts-bicarbonate ion and most preferably from about l.part fruit acid to about l.5 part to 5 parts bicarbonate ion. If a carbonate source is used in place of bicarbonate, the amount of fruit acid should be adjusted accordingly to maintain pH of neutral or greater in test solution. For example, the amount of fruit acid is 1 part fruit acid to about l to 20 parts bicarbonate ion, and preferably about 1 part fruit acid to about 1.5 to 10 parts bicarbonate ion and most preferably from about 1 part fruit acid to about 1.5 part to 5 parts bicarbonate ion.
Examples The following examples are intended to illustrate, but not to limit the present invention.
Example l:
Ingredient mass (Kg) xylitol (American Xyofin*) 1401 mannitol 250 aspartame (Nutrasweet*) 135 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49* [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
*Trade-mark lla Example 2 This example describes Applicant's preferred embodiment.
Ingredient mass (Kg) xylitol (American Xyofin) 1401 mannitol 250 aspartame (Nutrasweet) 135 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC#1) 1250 silica (ZEO-49 [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 polyvinyl pyrrolinone (PVP K-30* [FMC]) 89 magnesium stearate 20 stearic acid 65 *Trade-mark WO 98!03154 PCTIL1S97112460 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of polyvinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed. This cake was spread evenly onto trays and dried in an oven at less than 225°C until-completely dry (<1~
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about 1 to 2 hours in a tumble blender (or other blender of low shear} to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets:
Example 3: , This example describes a biologically active composi-tion with a peroxide source, which is incorporated to enhance the biological activity as we ll as cosmetic tooth whitening.
Incrredient mass (Kcr) xylitol (American Xyofin) 1560 mannitol 280 aspartame (Nutrasweet) 145 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 31 mint flavoring ~ 3.8 sodium bicarbonate (FMC #1) 1276 urea hydrogen peroxide (Robeko, N.Y.) 305 silica (ZEO-49 P.M. Huber Co.]) 418 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone (PVP K-30 [FMC]} 89 magnesium stearate 20 stearic acid 85 The sodium bicarbonate, silicon dioxide, PVP,~sodium lauryl sulfate are prepared in a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce a powder that can be tableted using a Stokes table press.
Example 4:
This example describes a biologically active composi-tion with a chlorine dioxide source, which is incorporated to enhance the biological activity, and for the treatment of halitosis.
Inaredient mass (Ka) xylitol (American Xyofin) 1560 mannitol 180 sorbitol 126 aspartame (Nutrasweet) 125 sodium lauryl sulfate (Witco) 20 chlorine dioxide source 2.5~
I - menthol crystals 35 mint flavoring 4.1 sodium bicarbonate (FMC #1) 1276 silica (ZEO-49 [J.M. Huber Co.]) 418 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone (PVP K-30 [FMC]) 89 magnesium stearate 20 stearic acid 85 The sodium bicarbonate, silicon dioxide, PVP, sodium lauryl sulfate are prepared in a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditi ons of low shear, to produce a powder that can be tableted using a Stokes table press.
Exampla 5:
This example describes a biologically active composition :with a Iodine source, which is incorporated to enhance the biological activity. , Ingredient mass (K
xylitol (American Xyofin) 1560 mannitol 280 aspartame (Nutrasweet) 145 sodium lauryl sulfate (Witco) ~ 20 1 - menthol crystals 31 mint flavoring 3.8 Povidone Iodine 33~
sodium bicarbonate (FMC #1) 1276 urea hydrogen peroxide (Robeko, N.Y.) 305 silica (ZEO-49 [J.M. Huber Co.]) 418 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone (PVP K-30 [FMC]) 89 magnesium stearate 20 stearic, acid 85 The sodium bicarbonate, silicon dioxide, PVP, sodium lauryl sulfate are prepared in a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditi ons of low shear, to produce a powder that can be tableted using a Stokes table press.
Example 6:
This example describes a highly biologically active composition with a chlorhexidine source, which is incorporated to enhance the biological activity.
Inaredient mass (Kcr) xylitol (American Xyofin) 1560 mannitol 280 aspartame (Nutrasweet) 145 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 31 mint flavoring 3.8 sodium bicarbonate {FMC #1) 1276 chlorhexidine gluconate 14.5 silica {ZEO-49 [J:M. Huber Co.]) 418 5 citric Acid (anhydrous crystals) 253 polyvinyl pyrrolinone {PVP K-30 [FMC]) 89 Neohesperidin dihydrochalcone (Exime) 6 magnesium stearate 20 stearic acid 85 10 The sodium bicarbonate, silicon dioxide, PVP, sodium lauryl sulfate are prepared yin a separate batch as mentioned in example 2. This and the remaining above ingredients are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to 15 produce a powder that can be tableted using a Stokes table press.
Example 7 This example describes a new example.
Incrredient mass (KQ) xylitol (American Xyofin) 1401 sorbitol 125 dextrose 145 aspartame (Nutrasweet) 128 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 21 mint flavoring 3.6 sodium bicarbonate (FMC#1) 1225 silica (ZEO-49[J.M. Huber Co.]) 401 citric Acid (anhydrous crystals) 238 polyvinyl pyrrolinone (PVP
K-30 [FMC] ) 82 ~ magnesium stearate 15 stearic acid 71 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of polyvinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed. This cake was spread evenly onto trays and dried in an oven at less than 225°C until-completely dry (<1~
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about l to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend: The powder is immediately pressed into tablets.
Example 8 Ingredient mass (Kg) xylitol (American Xyofin) 140 mannitol 1800 dextrose 700 aspartame (Nutrasweet) 135 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49 [J.M. Huber Co.J) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 9 This example describes a new example. ' Ingredient mass (Ka) xylitol (American Xyofin) 950 fructose 600 mannitol 307 aspartame (Nutrasweet) 100 ~ sodium lauryl sulfate (Witco) 20 1 - menthol crystals 27 . mint flavoring 2.9 sodium bicarbonate (FMC#1) 125 0 silica (ZEO-49[J.M. Huber Co:]) 310 silica (DeGusa) 52 citric Acid (anhydrous crystals) 205 tartaric acid 53 polyvinyl pyrrolinone (PVP
K-90 [FMC] ) 61 magnesium stearate 20 stearic acid 80 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of poly-vinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed.
This cake was spread evenly onto trays and dried in an oven at less than 225C until completely dry (<1%
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve., The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets.
Example 10:
Ingredient mass (Kct) xylitol (American Xyofin) 1250 mannitol 250 fructose 280 sorbitol 292 neohesperidin dihydrochalcone (NDHC Exquinne* [Spain]) 2 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49 [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 11 Ingredient mass (Kg) xylitol (American Xyofin) 250 maltodextrin 493 avisil pH 102 (FMC) 628 aspartame (Nutrasweet) 118 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 sodium bicarbonate (FMC #5) 1250 silica (ZEO-49 [J.M. Huber Co.]) 410 malic acid (anhydrous crystals) 243 polyvinyl pyrrolinone (PVP K-30 [FMC]) 89 magnesium stearate 20 stearic acid 65 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of polyvinyl pyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed. This cake was spread *Trade-mark 18a evenly onto trays and dried in an oven at less than 225°C until completely dry (<lo moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in . portions over about 1 to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets.
Example 12:
Inaredient mass (Kg?
xylitol (American Xyofin) 1401 mannitol 250 natural honey powder 790 sodium lauryl sulfate (Witco) 20 1 - menthol crystals 25 mint flavoring 3.6 potassium bicarbonate 290 sodium bicarbonate (FMC #1) 1320 Silica (ZEO-49 [J.M. Huber Co.]) 496 Citric Acid (anhydrous crystals) 243 tartaric acid 72 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 13 This example describes Applicant's preferred embodiment for a mint candy composition.
Ingredient mass tKct~
xylitol (American Xyofin) 1401 mannitol 250 sorbitol 375 ~ aspartame (Nutrasweet) 108 1 - menthol crystals 25 peppermint oil 2.3 sodium lauryl sulfate (Witco) 15 sodium bicarbonate (FMC#1) 1250 silica (ZEO-49[J.M. Huber Co.]) 420 citric Acid (anhydrous crystals) 243 polyvinyl alcohol (PVA) ' 103 glycerin 196 5 polyethylenglycol (PEG-60) 22 To a steam heated stainless steel kettle charged with 196 kg of anhydrous glycerin and 103 kg of PVA the mixture is stirred until an internal temperature of 80oC is maintained. To this is added in portions, with gentle l0 stirring, a blend of xylitol, mannitol and sorbitol and sodium lauryl sulfate. The resulting viscous slurry is stirred at between 75oC - 90oC until a homogenous mixture is obtained: The slurry is allowed to cool while stirring to an internal temperature of 500-600. A blend of NaHc03, 15 SiOz, is then added followed by the citric acid. The mixture is then cooled to form a cake. This cake is cut and/or pulverized to meet packaging requirements.
Exam~,ale 14:
Ingredient mass (Ka) 20 xylitol (American Xyofin) 1401 mannitol 250 aspartame (Nutrasweet) 135 1 - menthol crystals 25 mint flavoring 3.6 sodium lauryl sulfate (Witco) 20 sodium bicarbonate (FMC #1) 1250 Silica (ZEO-49 [J.M. Huber Co.]) 410 Citric Acid (anhydrous crystals) 243 The above are admixed in a rotating blender, and blended for at least 30 minutes under conditions of low shear, to produce an effervescent oral composition in powder form.
Example 15 This example describes appetite suppressive breath mint.
Incrredient mass (KQ) xylitol (American Xyofin) 1401 mannitol 250 ~ aspartame (Nutrasweet) 135 1 - menthol crystals 25 mint flavoring 3.6 sodium lauryl sulfate (Witco) 20 sodium bicarbonate (FMC#1) 1250 silica (ZEO-49[J.M. Huber Co.]) 410 citric Acid (anhydrous crystals) 243 polyvinyl pyrrolinone (PVP
K-30 [FMC]) 89 garcinio powder 28 magnesium stearate 24 1.5 stearic acid 65 In a separate batch mixer, the sodium bicarbonate, silicone dioxide, sodium lauryl sulfate, are admixed, and to this is added a lukewarm solution of 89 Kg of poly-vinylpyrrolinone (PVP) in 593 Kg of distilled water, and then this was mixed until a homogeneous cake was formed.
This cake was spread evenly onto trays and dried in an oven at less than 225°C until completely dry (<1~
moisture). This dried cake was then pulverized to a particle size of between 40 mesh and 100 mesh sieve. The powder was kept separate from the blend of the other components until the time of mixing. The blending process requires that the sodium bicarbonate-silicone dioxide powder admixed in portions over about 1 to 2 hours in a tumble blender (or other blender of low shear) to insure complete blending without the destruction of the binding properties of the blend. The powder is immediately pressed into tablets.
' It will be understood that the embodiments described herein are merely exemplary and that a person skilled in the art may make many variations and modifications without departing from the spirit and scope of the invention. All such modifications and variations are intended to be WO 98103154 PCTlUS97/12460 included within the scope of the invention as defined in the appended claims.
Claims (12)
1. An effervescent tablet or capsule of effervescent powder for oral use comprising, a) a non-aqueous, water soluble pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof;
b) silica; and c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
b) silica; and c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
2. An effervescent tablet or capsule of effervescent powder for oral use comprising:
a) a non-aqueous, water soluble pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof;
b) silica; and c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 1 to 3 and about 5 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
a) a non-aqueous, water soluble pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof;
b) silica; and c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 1 to 3 and about 5 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
3. An effervescent tablet or capsule of effervescent powder for oral use comprising, a) a non-aqueous, water soluble pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof;
b) silica; and (c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 2 to 3 and about 4 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
b) silica; and (c) xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 2 to 3 and about 4 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
4. An effervescent tablet or capsule of effervescent powder for oral use as in any one of claims 1 to 3 wherein the silica is amorphous silica.
5. A method for cleaning an oral cavity comprising the steps of:
(a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1;
(b) solubilizing said tablet or capsule powder;
(c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
(a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 0.5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1;
(b) solubilizing said tablet or capsule powder;
(c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
6. A method for cleaning an oral cavity comprising the steps of:
(a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 1 to 3 and about 5 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
(b) solubilizing said tablet or capsule powder;
(c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
(a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 1 to 3 and about 5 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1.
(b) solubilizing said tablet or capsule powder;
(c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
7. A method for cleaning an oral cavity comprising the steps of:
(a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 2 to 3 and about 4 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1;
(b) solubilizing said tablet or capsule powder;
(c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
(a) placing into an oral cavity an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 2 to 3 and about 4 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1;
(b) solubilizing said tablet or capsule powder;
(c) using the resulting saliva mixture to remove organic debris and biomass from the teeth; and (d) expelling or swallowing the resulting saliva mixture.
8. A method for cleaning an oral cavity as in claims 5, 6 or 7 wherein the silica is amorphous silica.
9. Use of an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about .5 to 3 and about 7 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1, in cleaning the oral cavity of an animal.
10. Use of an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 1 to 3 and about 5 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1, in cleaning the oral cavity of an animal.
11. Use of an effervescent tablet or capsule of effervescent powder for oral use having a non-aqueous, water soluble, pharmaceutically acceptable carbon dioxide source selected from the group consisting of bicarbonate salt, carbonate salt, and mixtures thereof; silica and xylitol wherein the ratio of the weight of said xylitol to the weight of said bicarbonate and silica is between about 2 to 3 and about 4 to 3 and the ratio of the weight of said xylitol to said silica is less than 10 to 1; in cleaning the oral cavity of an animal.
12. Use according to any one of claims 9 to 11 wherein the silica is amorphous silica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/685,703 | 1996-07-24 | ||
US08/685,703 US5804165A (en) | 1996-07-24 | 1996-07-24 | Antiplaque oral composition |
PCT/US1997/012460 WO1998003154A1 (en) | 1996-07-24 | 1997-07-17 | Antiplaque oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2261659A1 CA2261659A1 (en) | 1998-01-29 |
CA2261659C true CA2261659C (en) | 2001-09-18 |
Family
ID=24753338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002261659A Expired - Fee Related CA2261659C (en) | 1996-07-24 | 1997-07-17 | Antiplaque oral composition |
Country Status (12)
Country | Link |
---|---|
US (2) | US5804165A (en) |
EP (1) | EP0921783B1 (en) |
JP (2) | JP3944242B2 (en) |
KR (1) | KR100322807B1 (en) |
CN (1) | CN1154469C (en) |
AT (1) | ATE190834T1 (en) |
AU (1) | AU729826B2 (en) |
BR (1) | BR9710554A (en) |
CA (1) | CA2261659C (en) |
DE (1) | DE69701532T2 (en) |
HK (1) | HK1023727A1 (en) |
WO (1) | WO1998003154A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817294A (en) * | 1990-11-02 | 1998-10-06 | Arnold; Michael J. | Plaque adsorbent oral composition and method |
US5804165A (en) * | 1996-07-24 | 1998-09-08 | Arnold; Michael J. | Antiplaque oral composition |
PL338922A1 (en) * | 1997-09-02 | 2000-11-20 | Unilever Nv | Oral compositions |
US6428770B1 (en) * | 1997-12-03 | 2002-08-06 | Kao Corporation | Solid preparation for oral hygiene |
JP2000191429A (en) * | 1998-12-28 | 2000-07-11 | Kao Corp | Foamable cosmetic |
US6238648B1 (en) | 1999-03-25 | 2001-05-29 | The Procter & Gamble Company | Anti-caries oral care compositions and their methods of use |
GB0007762D0 (en) * | 2000-03-30 | 2000-05-17 | Smithkline Beckman Corp | Composition |
US20030206876A1 (en) * | 2000-03-30 | 2003-11-06 | Buch Robert Michael | Composition |
GB0018849D0 (en) * | 2000-08-01 | 2000-09-20 | Smithkline Beecham Plc | Novel composition and use |
US6867343B2 (en) * | 2000-10-27 | 2005-03-15 | Kimberly-Clark Worldwide, Inc. | Odor control absorbent article and method |
US6437212B1 (en) * | 2000-10-27 | 2002-08-20 | Kimberly-Clark Worldwide, Inc. | Reduced odor absorbent article and method |
TW527745B (en) | 2000-11-21 | 2003-04-11 | Dainichiseika Color Chem | Solidifying material for cell electrolyte solution, and cell comprising the solidifying material |
JP4762429B2 (en) * | 2001-04-03 | 2011-08-31 | 日本ゼトック株式会社 | Oral composition |
GB0211576D0 (en) * | 2002-05-21 | 2002-06-26 | Cheetham J K | A novel formula for modification of chemical compounds on flavour solubility and stability |
US6984377B2 (en) * | 2002-05-29 | 2006-01-10 | J. M. Huber Corporation | Oral care products comprising calcium metasilicates |
JP4482270B2 (en) * | 2002-10-31 | 2010-06-16 | 花王株式会社 | Oral composition |
US20040101493A1 (en) * | 2002-11-26 | 2004-05-27 | Scott Douglas Craig | Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth |
US20040101494A1 (en) * | 2002-11-26 | 2004-05-27 | Scott Douglas Craig | Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth |
US6776979B2 (en) * | 2002-12-30 | 2004-08-17 | Marvin B. Frager | Periodontal treatment compound and method of use |
US20050069503A1 (en) * | 2003-03-10 | 2005-03-31 | Larsen Robert K. | Tooth whitening mouthwashes and methods for making and using them |
US20040223921A1 (en) * | 2003-05-07 | 2004-11-11 | Rau Allen H. | Oral care tablet |
KR20150038745A (en) * | 2004-02-17 | 2015-04-08 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US20050244347A1 (en) * | 2004-04-30 | 2005-11-03 | Mehra Dev K | Oral care products comprising calcium phosphates |
US20070196477A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area calcium phosphates |
US20050244343A1 (en) * | 2004-04-30 | 2005-11-03 | Withiam Michael C | Oral care products comprising silica |
US9968526B1 (en) | 2005-01-24 | 2018-05-15 | Dental Alliance Holdings, Lll | System for caries management by risk assessment |
WO2006097427A1 (en) * | 2005-03-16 | 2006-09-21 | Symrise Gmbh & Co. Kg | Menthol-containing solids composition |
US20090191510A1 (en) * | 2005-06-22 | 2009-07-30 | Cao Group, Inc. | Periodontal treatment employing applied ultrasonic energy |
US20070071817A1 (en) * | 2005-09-26 | 2007-03-29 | Phyzz, Inc. | Effervescent oral care compositions and method of use |
US9067082B2 (en) * | 2006-07-26 | 2015-06-30 | Ultradent Products, Inc. | Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions |
US10143633B2 (en) | 2006-10-16 | 2018-12-04 | Dental Alliance Holdings, Llc | Treating cariogenic diseased oral biofilm with elevated pH |
US20090053309A1 (en) * | 2007-08-24 | 2009-02-26 | Axiomedic Ltd., Gibraltar | Adhesive compositions for the treatment of xerostomia |
US9161909B2 (en) * | 2007-08-24 | 2015-10-20 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostomia |
EP2100642A1 (en) * | 2008-03-13 | 2009-09-16 | 3M Innovative Properties Company | Composition containing a water-miscible liquid and water-soluble particles, method of production and use thereof |
US8801436B2 (en) * | 2008-04-02 | 2014-08-12 | Carson Laboraotories, I, P., Inc. | Oral hygiene composition and apparatus and method |
US9849310B2 (en) * | 2008-06-24 | 2017-12-26 | Dental Alliance Holdings, Llc | Dental appliance, oral care product and method of preventing dental disease |
EP2760417B1 (en) * | 2011-09-30 | 2020-11-11 | Rubicon Research Private Limited | Oral care compositions |
WO2014042120A1 (en) * | 2012-09-13 | 2014-03-20 | ライオン株式会社 | Foaming oral composition, foaming oral solid preparation and foaming oral product |
JP5868310B2 (en) * | 2012-12-11 | 2016-02-24 | 合同会社地球環境・麦飯石研究所 | Plaque remover |
EP3074026B1 (en) * | 2013-11-25 | 2020-01-08 | D.T.R. Dermal Therapy Research Inc. | Composition, system and method for treating skin |
ES2749866T3 (en) * | 2014-05-01 | 2020-03-24 | Hermes Arzneimittel Gmbh | Solid oral formulations comprising solid molten dispersions of organic acids in xylitol |
JP2018534323A (en) * | 2015-11-19 | 2018-11-22 | シニュー・ファーマ・インコーポレイテッドSiNew Pharma Inc. | Pharmaceutical composition for prevention or treatment of fatty liver |
GB2545007A (en) | 2015-12-03 | 2017-06-07 | Cosmetic Warriors Ltd | Composition |
GB201701869D0 (en) | 2017-02-04 | 2017-03-22 | Swish Ip Holdings Ltd | Oral Hygiene Compositions |
JP7163623B2 (en) * | 2017-05-31 | 2022-11-01 | ライオン株式会社 | Dentifrice composition and unpleasant taste reducer |
EP3655469A1 (en) * | 2017-07-20 | 2020-05-27 | Solvay Sa | Functionalized particulate bicarbonate as blowing agent, foamable polymer composition containing it, and its use in manufacturing a thermoplastic foamed polymer |
US11141364B2 (en) * | 2017-11-30 | 2021-10-12 | Colgate-Palmolive Company | Oral care compositions |
WO2020010048A1 (en) | 2018-07-06 | 2020-01-09 | Mccormick Lindsay | Natural tooth powder tablets |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US975814A (en) * | 1906-03-29 | 1910-11-15 | Albert Westlake | Mouth-tablet. |
US975354A (en) * | 1909-05-04 | 1910-11-08 | Chemische Werke Vorm Dr Heinrich Byk | Stable mixture of producing hydrogen peroxid. |
US1082681A (en) * | 1912-01-31 | 1913-12-30 | William Edward Danner | Tooth-powder. |
US1112180A (en) * | 1913-03-08 | 1914-09-29 | Charles W Westenfelter | Dentifrice. |
US1275275A (en) * | 1915-06-19 | 1918-08-13 | Samuel Levinston | Mouth toilet preparation. |
US1262888A (en) * | 1917-02-20 | 1918-04-16 | Albert Westlake | Mouth-tablet. |
USRE14961E (en) * | 1918-03-05 | 1920-10-19 | Meyer l | |
US1516398A (en) * | 1923-01-15 | 1924-11-18 | Mcdowell Charles | Gum dentifrice |
US2035267A (en) * | 1934-02-10 | 1936-03-24 | Louis Schumacher | Effervescent sodium perborate |
US2218172A (en) * | 1934-10-13 | 1940-10-15 | Autoxygen Inc | Preparation for antisepsis of the oral cavity |
US2820000A (en) * | 1953-04-03 | 1958-01-14 | Menzies Alfred | Dentifrice comprising diatomaceous silica |
US2868655A (en) * | 1956-12-31 | 1959-01-13 | Internat Salt Company Inc | Salt tablets containing an ethylenediaminetetracetic acid compound and process of producing the same |
US2951791A (en) * | 1959-08-31 | 1960-09-06 | American Cyanamid Co | Use of calcium silicate in tablet compressing |
FR280067A (en) * | 1960-11-17 | |||
US3227521A (en) * | 1961-01-17 | 1966-01-04 | Reynolds Metals Co | Process for producing substantially kappa-phase alumina |
DE1165182B (en) * | 1961-06-28 | 1964-03-12 | Du Pont | Pigment based on translucent mica-like flakes and process for its manufacture |
US3136692A (en) * | 1961-06-30 | 1964-06-09 | Strong Cobb Arner Inc | Effervescent composition containing polyvinylpyrrolidone |
US3330732A (en) * | 1964-06-11 | 1967-07-11 | Indiana University Foundation | Cleaning and polishing agent for dental prophylaxis |
US3372125A (en) * | 1965-11-15 | 1968-03-05 | Peter Strong & Company Inc | Denture cleanser |
US3431339A (en) * | 1966-07-20 | 1969-03-04 | Colgate Palmolive Co | Dentifrices |
US3432338A (en) * | 1967-04-17 | 1969-03-11 | Diamond Shamrock Corp | Electroless nickel,cobalt and nickel-cobalt alloy plating from fluoborates sources |
US3518343A (en) * | 1967-10-02 | 1970-06-30 | Miles Lab | Effervescent tablet and process for making same |
US3577490A (en) * | 1967-10-02 | 1971-05-04 | Miles Lab | Effervescent tablet and process for making same |
US3577492A (en) * | 1967-10-02 | 1971-05-04 | Miles Lab | Tableting lubricant |
US3518344A (en) * | 1967-10-02 | 1970-06-30 | Miles Lab | Tableting lubricant |
US3518345A (en) * | 1967-10-05 | 1970-06-30 | Miles Lab | Tableting lubricant |
US3488288A (en) * | 1968-03-04 | 1970-01-06 | Peter Strong & Co Inc | Denture cleansers |
US3574824A (en) * | 1968-05-03 | 1971-04-13 | Warner Lambert Pharmaceutical | Anhydrous toothpaste formulation |
GB1259342A (en) * | 1969-02-04 | 1972-01-05 | ||
US3629468A (en) * | 1969-04-21 | 1971-12-21 | Howard P Andersen | Hygroscopically controlled effervescent mouthwash tablet |
US3914434A (en) * | 1969-08-22 | 1975-10-21 | Hoffmann La Roche | Non-cariogenic foods and delicacies containing xylitol as a sugar substitute |
CH524319A (en) * | 1969-08-22 | 1972-06-30 | Hoffmann La Roche | Process for the production of sweetener-containing, tooth-friendly or non-cariogenic food and luxury foods |
DE2051499A1 (en) * | 1969-10-20 | 1971-04-29 | Warner Lambert Pharmaceutical Co , Morns Plains, NJ (V St A ) | Effervescent compositions containing fluid |
US3670076A (en) * | 1970-03-31 | 1972-06-13 | Indiana University Foundation | Dental prophylaxis composition comprising alumina of particular particle size |
US3767791A (en) * | 1971-06-03 | 1973-10-23 | Colgate Palmolive Co | Dental cream containing abrasive agglomerates |
US3821117A (en) * | 1971-07-23 | 1974-06-28 | Carter Wallace | Effervescent tablet |
US4180467A (en) * | 1971-10-07 | 1979-12-25 | Colgate-Palmolive Company | Stable denture soak product |
US3772431A (en) * | 1972-09-21 | 1973-11-13 | W Mlkvy | Effervescent mouthwash tablet |
US3888976A (en) * | 1972-09-21 | 1975-06-10 | William P Mlkvy | Zinc and strontium ion containing effervescent mouthwash tablet |
US3935305A (en) * | 1972-10-04 | 1976-01-27 | Colgate-Palmolive Company | Toothpaste |
US3937804A (en) * | 1972-10-04 | 1976-02-10 | Colgate-Palmolive Company | Toothpaste |
US3937803A (en) * | 1972-10-04 | 1976-02-10 | Colgate-Palmolive Company | Flavored dental creams |
US3937321A (en) * | 1972-10-04 | 1976-02-10 | Colgate-Palmolive Company | Toothpaste |
US3932604A (en) * | 1972-12-22 | 1976-01-13 | Colgate-Palmolive Company | Humectant sweetener |
US3962417A (en) * | 1974-03-27 | 1976-06-08 | Howell Charles J | Dentifrice |
US3976601A (en) * | 1974-06-24 | 1976-08-24 | Johnson & Johnson | Water soluble lubricant for tabletting compositions |
US4062793A (en) * | 1975-01-14 | 1977-12-13 | Blendax-Werke R. Schneider Gmbh & Co. | Cleaning agents for dentures |
US4181621A (en) * | 1975-07-08 | 1980-01-01 | Blendax-Werke R. Schneider & Co. | Cleaning agents for dentures |
AU510235B2 (en) * | 1975-12-22 | 1980-06-19 | Johnson & Johnson | Denture cleanser tablet |
US4127645A (en) * | 1976-05-21 | 1978-11-28 | Life Savers, Inc. | Effervescent tablet and method |
US4157386A (en) * | 1978-05-18 | 1979-06-05 | Rochelle Paul J | Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushing |
GB2047091B (en) * | 1979-04-19 | 1983-05-18 | Muhlemann H R | Orally administrable compositions containing urea hydrogen peroxide |
US4367218A (en) * | 1979-09-06 | 1983-01-04 | Jacobson Jerry I | Anti-caries oral rinse |
US4308252A (en) * | 1979-10-31 | 1981-12-29 | Young Dental Mfg. Co. | Dentifrice composition |
US4267164A (en) * | 1980-01-31 | 1981-05-12 | Block Drug Company Inc. | Effervescent stannous fluoride tablet |
US4411885A (en) * | 1980-09-30 | 1983-10-25 | Barels Ronald R | Vitamin E oil based dentifrice |
US4487757A (en) * | 1981-12-28 | 1984-12-11 | Colgate-Palmolive Company | Dispensing container of toothpaste which effervesces during toothbrushing |
US4414198A (en) * | 1982-04-23 | 1983-11-08 | Joseph Michaelson | Rapidly disintegrable tablet composition and method |
US4537778A (en) * | 1983-01-03 | 1985-08-27 | Colgate-Palmolive Company | Oral preparation |
US4983379A (en) * | 1983-03-01 | 1991-01-08 | Schaeffer Hans A | Dental preparation, article and method for storage and delivery thereof |
US4528180A (en) * | 1983-03-01 | 1985-07-09 | Schaeffer Hans A | Dental preparation, article and method for storage and delivery thereof |
US4971782A (en) * | 1983-09-14 | 1990-11-20 | Peroxydent Group | Periodontal composition and method |
US4647451A (en) * | 1984-05-11 | 1987-03-03 | Colgate-Palmolive Company | Anhydrous dentifrice |
GB8421226D0 (en) * | 1984-08-21 | 1984-09-26 | Int Conferences Ab | Tooth cleaning tablet |
US4627972A (en) * | 1984-11-16 | 1986-12-09 | Union Carbide Corporation | Effervescent dentifrice |
US4818518A (en) * | 1984-11-16 | 1989-04-04 | Uop | Effervescent dentifrice |
DK161428C (en) * | 1985-05-10 | 1991-12-16 | Fertin Lab As | SOLID, ORAL CARIAL EFFECTS |
US4592487A (en) * | 1985-07-03 | 1986-06-03 | Simon Gilbert I | Dentifrices |
WO1987001936A1 (en) * | 1985-09-25 | 1987-04-09 | Gerhard Gergely | Desintegration tablet and process for its manufacture |
JPH02504030A (en) * | 1987-06-25 | 1990-11-22 | デンタブ・インコーポレーテッド | Tablets that clean teeth and add fluoride |
US5028414A (en) * | 1987-07-17 | 1991-07-02 | The Procter & Gamble Company | Anaerobe-selective antibacterial compositions and methods |
DE3725248A1 (en) * | 1987-07-30 | 1989-02-09 | Henkel Kgaa | ANTIMICROBIAL EFFICIENT, FLAVORED PREPARATIONS |
US4980154A (en) * | 1988-06-23 | 1990-12-25 | Norman Gordon | Tooth and gum dentifrice composition and method of making same |
KR970004033B1 (en) * | 1989-02-15 | 1997-03-24 | 로날드 케이 뮤러마 | Teeth whitener |
US5000941A (en) * | 1989-05-16 | 1991-03-19 | Milton P. Chernack | Dentifrice containing microencapsulated oxygen |
US5008106A (en) * | 1989-12-14 | 1991-04-16 | Gaf Chemicals Corporation | Method for reducing the microbial content of surfaces with a microbiocidal, anhydrous complex of PVP-H2 O2 |
US5817294A (en) * | 1990-11-02 | 1998-10-06 | Arnold; Michael J. | Plaque adsorbent oral composition and method |
US5204115A (en) * | 1990-12-12 | 1993-04-20 | Suomen Xyrofin Oy | Directly compressible xylitol and method |
ATE140621T1 (en) * | 1993-04-15 | 1996-08-15 | Gergely Gerhard | SHOWER SYSTEM WITH AN ALKALINE AND/OR METAL SENSITIVE PHARMACEUTICAL ACTIVE INGREDIENT, AND METHOD FOR PRODUCTION |
US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
IL112779A (en) * | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
BR9507495A (en) * | 1994-04-22 | 1997-08-12 | Dibona Holding Ag | Bullet to suck with neutralizing action of the dental plaque |
US5571441A (en) * | 1994-11-01 | 1996-11-05 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
US5869095A (en) * | 1995-07-31 | 1999-02-09 | Gerhard Gergely | Chewable tablet with an effervescent action |
IT1282650B1 (en) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS |
US5804165A (en) * | 1996-07-24 | 1998-09-08 | Arnold; Michael J. | Antiplaque oral composition |
-
1996
- 1996-07-24 US US08/685,703 patent/US5804165A/en not_active Expired - Fee Related
-
1997
- 1997-07-17 AT AT97933525T patent/ATE190834T1/en active
- 1997-07-17 JP JP50707398A patent/JP3944242B2/en not_active Expired - Fee Related
- 1997-07-17 EP EP97933525A patent/EP0921783B1/en not_active Expired - Lifetime
- 1997-07-17 KR KR1019997000554A patent/KR100322807B1/en not_active IP Right Cessation
- 1997-07-17 WO PCT/US1997/012460 patent/WO1998003154A1/en active IP Right Grant
- 1997-07-17 CN CNB971977445A patent/CN1154469C/en not_active Expired - Fee Related
- 1997-07-17 CA CA002261659A patent/CA2261659C/en not_active Expired - Fee Related
- 1997-07-17 DE DE69701532T patent/DE69701532T2/en not_active Expired - Lifetime
- 1997-07-17 BR BR9710554-6A patent/BR9710554A/en not_active IP Right Cessation
- 1997-07-17 AU AU36691/97A patent/AU729826B2/en not_active Ceased
-
1998
- 1998-08-19 US US09/136,631 patent/US6086854A/en not_active Expired - Fee Related
-
2000
- 2000-05-17 HK HK00102944A patent/HK1023727A1/en not_active IP Right Cessation
-
2006
- 2006-03-06 JP JP2006059895A patent/JP4444925B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0921783A1 (en) | 1999-06-16 |
BR9710554A (en) | 2000-01-11 |
CN1235536A (en) | 1999-11-17 |
CN1154469C (en) | 2004-06-23 |
US5804165A (en) | 1998-09-08 |
AU729826B2 (en) | 2001-02-08 |
WO1998003154A1 (en) | 1998-01-29 |
ATE190834T1 (en) | 2000-04-15 |
DE69701532T2 (en) | 2000-11-09 |
JP2006182790A (en) | 2006-07-13 |
EP0921783B1 (en) | 2000-03-22 |
US6086854A (en) | 2000-07-11 |
JP3944242B2 (en) | 2007-07-11 |
AU3669197A (en) | 1998-02-10 |
DE69701532D1 (en) | 2000-04-27 |
JP2000501422A (en) | 2000-02-08 |
HK1023727A1 (en) | 2000-09-22 |
KR100322807B1 (en) | 2002-03-15 |
CA2261659A1 (en) | 1998-01-29 |
KR20000068003A (en) | 2000-11-25 |
JP4444925B2 (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2261659C (en) | Antiplaque oral composition | |
US5965110A (en) | Plaque adsorbent oral composition and method | |
US10058497B2 (en) | Oral hygiene products and method of using the same | |
US3962417A (en) | Dentifrice | |
AU2006320846B2 (en) | Vehicles for oral care with Magnolia Bark Extract | |
US8192724B2 (en) | Oral care tablet | |
JPH0776510A (en) | Oral hygiene promoting composition containing bamboo salt | |
JPH01501472A (en) | Composition for prolonging the action of antiplaque agents | |
JPH07108851B2 (en) | Oral composition for preventing solid pimples | |
US20070071817A1 (en) | Effervescent oral care compositions and method of use | |
JP3793625B2 (en) | Powder dentifrice composition | |
US10857078B2 (en) | Powder oral hygiene compositions and methods for their manufacture | |
KR101932534B1 (en) | Method for manufacturing the foamy tablet for the mouth clean | |
JP2018535981A (en) | Composition | |
KR20020086064A (en) | Charcoal powder-containing dentifrice composition for removing nicotine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |